THe Australian Self-Medication
Industry has vowed to continue
its advocacy for Schedule 3
advertising reforms, in the face of
recommendations that restrictions
be retained in the State Two Expert
Panel report on the regulatory
framework for medicines and
medical devices (PD Fri).
Despite suggesting some
revisions, to provide for a formal
risk-benefit methodology for S3
items to be included in Appendix
H, the panel didn’t recommend
removing all S3 ad restrictions.
However ASMI chief executive
officer Deon Schoombie said the
organisation supports the majority
of the report, saying “we are
pleased the Panel recommended a
risk-based approach to regulation
and accepted many of the
proposals industry put forward”.
Schoombie said ASMI reserves
judgement about the Panel’s
recommendations on complaints
handling and pre-vetting of
advertisements “as these two areas
are highly complex, involve several
inter-connected systems and
will require a suite of additional
reforms”.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Nov 15
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.